# Biodistribution Study of CMD-193 in Patients With Advanced Tumours Expressing the Lewis-Y Antigen

> **NCT00293215** · PHASE1 · TERMINATED · sponsor: **Ludwig Institute for Cancer Research** · enrollment: 9 (actual)

## Conditions studied

- Neoplasms

## Interventions

- **DRUG:** 111-Indium-CMD-193
- **DRUG:** CMD-193

## Key facts

- **NCT ID:** NCT00293215
- **Lead sponsor:** Ludwig Institute for Cancer Research
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-02
- **Primary completion:** 2007-05
- **Final completion:** 2007-05
- **Target enrollment:** 9 (ACTUAL)
- **Why stopped:** Abnormal distribution and lack of tumor targeting were observed.
- **Last updated:** 2022-10-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00293215

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00293215, "Biodistribution Study of CMD-193 in Patients With Advanced Tumours Expressing the Lewis-Y Antigen". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00293215. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*